You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Litigation Details for Silbersher v. Valeant Pharmaceuticals International, Inc (N.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Silbersher v. Valeant Pharmaceuticals International, Inc (N.D. Cal. 2018)

Docket ⤷  Try a Trial Date Filed 2018-03-07
Court District Court, N.D. California Date Terminated 2020-07-02
Cause 31:3729 False Claims Act Assigned To James Donato
Jury Demand Plaintiff Referred To
Parties ADAMAS PHARMACEUTICALS, INC.; COMMONWEALTH OF MASSACHUSETTS; COMMONWEALTH OF VIRGINIA; DISTRICT OF COLUMBIA; DR. FALK PHARMA GMBH; SALIX PHARMACEUTICALS, INC; SALIX PHARMACEUTICALS, LTD.; STATE OF CALIFORNIA; STATE OF COLORADO; STATE OF CONNECTICUT; STATE OF DELAWARE; STATE OF FLORIDA; STATE OF GEORGIA; STATE OF HAWAII; STATE OF ILLINOIS; STATE OF INDIANA; STATE OF IOWA; STATE OF LOUISIANA; STATE OF MARYLAND; STATE OF MICHIGAN; STATE OF MINNESOTA; STATE OF MONTANA; STATE OF NEVADA; STATE OF NEW HAMPSHIRE; STATE OF NEW JERSEY; STATE OF NEW MEXICO; STATE OF NEW YORK; STATE OF NORTH CAROLINA; STATE OF OKLAHOMA; STATE OF RHODE ISLAND; STATE OF TENNESSEE; STATE OF TEXAS; STATE OF VERMONT; STATE OF WASHINGTON; UNITED STATES OF AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC; ZACHARY SILBERSHER
Patents 10,000,565; 10,004,743; 10,004,745; 10,005,847; 10,028,937; 10,028,946; 10,028,993; 10,052,468; 10,065,993; 10,138,297; 10,201,537; 10,201,544; 10,280,468; 10,293,040; 10,293,045; 10,293,047; 10,294,299; 10,317,410; 10,457,666; 10,457,711; 10,537,563; 10,537,627; 10,544,099; 10,544,108; 10,550,122; 10,555,537; 10,555,939; 10,555,993; 10,570,103; 10,570,175; 10,570,202; 10,570,457; 6,030,623; 6,133,999; 6,136,559; 6,280,993; 6,290,993; 6,468,559; 6,537,666; 6,551,620; 6,573,293; 6,662,810; 6,696,090; 6,745,776; 6,765,668; 6,774,122; 6,939,376; 6,946,098; 7,017,745; 7,030,665; 7,033,998; 7,052,679; 7,094,781; 7,122,183; 7,122,544; 7,122,592; 7,201,679; 7,280,816; 7,531,623; 7,550,294; 7,563,810; 7,592,004; 7,592,008; 7,592,021; 7,662,052; 7,662,573; 7,666,616; 7,740,544; 7,741,098; 7,741,345; 7,745,409; 7,745,460; 7,745,571; 7,816,080; 7,939,468; 7,946,960; 7,960,311; 7,988,998; 7,999,072; 8,017,592; 8,017,741; 8,034,765; 8,034,946; 8,038,988; 8,042,531; 8,052,993; 8,080,537; 8,201,556; 8,202,537; 8,293,742; 8,293,885; 8,298,556; 8,299,116; 8,337,886; 8,376,993; 8,409,038; 8,409,574; 8,409,616; 8,410,082; 8,410,136; 8,457,988; 8,460,662; 8,460,704; 8,496,965; 8,529,939; 8,563,688; 8,563,690; 8,571,805; 8,573,565; 8,574,102; 8,574,544; 8,574,856; 8,592,401; 8,623,410; 8,623,865; 8,627,816; 8,679,069; 8,679,460; 8,679,520; 8,679,544; 8,741,592; 8,741,847; 8,741,885; 8,742,183; 8,781,571; 8,812,100; 8,816,108; 8,865,623; 8,865,679; 8,865,688; 8,865,743; 8,865,885; 8,865,937; 8,865,954; 8,937,042; 8,946,175; 8,946,183; 8,946,250; 8,993,019; 8,993,250; 8,993,520; 8,998,876; 8,999,668; 9,072,742; 9,072,781; 9,089,570; 9,090,688; 9,090,876; 9,095,559; 9,096,666; 9,096,688; 9,096,876; 9,102,573; 9,102,742; 9,138,410; 9,138,627; 9,290,574; 9,297,812; 9,345,701; 9,376,662; 9,408,993; 9,409,074; 9,410,138; 9,410,954; 9,457,065; 9,457,096; 9,592,293; 9,616,088; 9,616,096; 9,623,001; 9,623,022; 9,623,034; 9,623,041; 9,623,090; 9,623,118; 9,662,401; 9,688,665; 9,688,711; 9,688,765; 9,701,741; 9,765,138; 9,765,298; 9,810,696; 9,816,103; 9,856,065; 9,937,183; 9,937,250; 9,993,005; 9,993,529; 9,993,555; 9,993,556
Attorneys Andrew Michael Purdy; Anthony Louis Portelli; Bret Douglas Hembd; Charles Jacob Gower; Christian Emile Mammen; Christopher Cormier; Daniel Cullen Sheehan; David Bruce Zlotnick; Jennifer S Wang; John Bourke; Joseph R. Saveri; Kevin E. Rayhill; Kristen H Cramer; Kyla Jenny Gibboney; Laura E Seidl; Mary W Bourke; Michelle Lo; Moez Mansoor Kaba; Nicomedes Sy Herrera; Padraic William Foran; Shawn M. Kennedy; Steven N. Feldman; Tejinder Singh; V Chai Oliver Prentice; Warren Tavares Burns
Firms Burns Charest LLP; Goldstein & Russell, P.C.; Herrera Purdy LLP; Herrera Purdy Weiler LLP; Hueston Hennigan LLP; Joseph Saveri Law Firm; Joseph Saveri Law Firm, Inc.; United States Attorney's Office; United States Attorney's Office, Northern District of California; Womble Bond Dickinson (US) LLP
Link to Docket External link to docket
Biologic Drugs cited in Silbersher v. Valeant Pharmaceuticals International, Inc

The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .

Details for Silbersher v. Valeant Pharmaceuticals International, Inc (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-03-07 1 Complaint the Otterbeck Patents. 26 4 27 The Otterbeck Patents are U.S. Patent Nos. 6,551,620 ("the …Otterbeck Patent to be approved, United States 21 Patent No. 6,551,620 ("the '620 Patent"…See e.g., U.S. Patent No. 6,551,620 at col. 5, lines 15-19. 4 70. Apriso® is a granulated…. Patent No. 8,865,688 ("the '688 Patent"). The '688 Patent was issued 3 on October… United States Patent Law 11 64. United States patents grant the patent owner or assignee External link to document
2018-10-23 10 Amended Complaint Otterbeck Patent to be approved, United States Patent No. 6,551,620 (“the ’620 Patent”). The ’620 Patent issued… Patent Nos. 6,551,620 (“the 7620 Patent”), 8,337,886 (“the ’886 Patent”), 8,496,965 (“the ’965 Patent….g., U.S. Patent No. 6,551,620 at col. 5, lines 15-19. 76. Apriso® is a granulated mesalamine formulation…knew that ’990 Patent, the’742 Patent, the ’858 Patent, and the “EP0169821A2 Patent patents were all in … when the Patent Office’s Patent Trial and Appeal Board (“PTAB”) invalidated the 688 Patent on the grounds External link to document
2020-05-11 109 Order on Motion to Dismiss After the ’688 patent was issued, generics manufacturers sued to invalidate it. Dkt. No. 10 …intentionally withheld [prior art] from the Patent Office,” Dkt. No. 10 ¶ 15, and … 7 Raytheon Co., 816 F.3d 565, 574 (9th Cir. 2016); see also Schindler, 563 U.S…defendants fraudulently obtained U.S. Patent No. 8,865,688 (the “’688 patent”), which … 18 Patent and Trademark Office (“USPTO”) issued the ’688 patent, which has been assigned External link to document
2023-08-03 123 USCA Order , and the PTO granted Patent No. 8,865,688 (“the ’688 Patent”) in 2014.6 Valeant’s… of obtaining a patent is called a patent prosecution. In a patent prosecution, an… the patent argues against the validity of the patent, and the patent owner defends…Otterbeck Patents rested on shaky ground. Several patents predating the Otterbeck Patents describe…for the ’688 Patent, Valeant had applied for Patent No. 8,921,344 (“the ’344 Patent”). In the External link to document
2024-01-05 127 USCA Order succeeded, and the PTO granted Patent No. 8,865,688 (“the ’688 Patent”) in 2014.6 Valeant’s 6…process of obtaining a patent is called a patent prosecution. In a patent prosecution, an inventor…challenging the patent argues against the validity of the patent, and the patent owner defends it…Otterbeck Patents rested on shaky ground. Several patents predating the Otterbeck Patents describe…for the ’688 Patent, Valeant had applied for Patent No. 8,921,344 (“the ’344 Patent”). In the ’344 External link to document
2019-01-14 36 Appendix Appendix A U.S. Patent No. 6,290,990 (Ex. D-1). Patent, the ’858 Patent, and ¶¶ 106-115 Patent, the ’742…742 Patent, the ’858 European Patent Patent, and European Patent …prosecuted both patents is disclosed in the ’344 Patent application the patents themselves,… contained in the patents U.S. Patent No. 4,784,858 (Ex. D-3). Otterbeck Patents invalid. …The ’344 Patent disclosed Complaint This disclosure is contained in the U.S. Patent No. 8,921,344 External link to document
2019-02-18 45 Appendix 1 U.S. Patent No. 6,551,620 (Ex. C-1). The patent prosecution docket available on Patents asserted…from: Patent, and European Patent, and European Patent U.S. Patent No.…granting the ’688 Patent were Patent Application No. 12/573,081, Sep. ’688 Patent does not disclose… Office The PAIR patent docket for the ’688 Patent the ’688 Patent, 96 …granting the ’688 Patent were Patent Application No. 12/573,081, Sep. ’688 Patent does not disclose External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.